Gastro Esophageal Junction Cancer Terminated Phase 3 Trials for Nimotuzumab (DB06192)

Also known as: Gastroesophageal-junction Cancer / Gastroesophageal Junction Cancer / Gastro-oesophageal Junction Cancer / Gastro-esophageal Junction Cancer / Gastrooesophageal junction cancer / Carcinoma of oesophagus NOS / Carcinoma of oesophagus / Carcinoma of esophagus (disorder) / Carcinoma of esophagus / Oesophageal carcinoma NOS / Oesophageal carcinoma / Esophageal carcinoma NOS / Esophageal carcinoma / Primary malignant neoplasm of esophagus (disorder)

IndicationStatusPhase
DBCOND0106887 (Gastro Esophageal Junction Cancer)Terminated3
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01813253Phase 3 Study of Nimotuzumab and Irinotecan as Second Line With Advanced or Recurrect Gastric and Gastroesophageal Junction CancerTreatment